DK1968630T5 - Multivalente pcv2-immunogeniske sammensætninger. - Google Patents
Multivalente pcv2-immunogeniske sammensætninger. Download PDFInfo
- Publication number
- DK1968630T5 DK1968630T5 DK06848471.6T DK06848471T DK1968630T5 DK 1968630 T5 DK1968630 T5 DK 1968630T5 DK 06848471 T DK06848471 T DK 06848471T DK 1968630 T5 DK1968630 T5 DK 1968630T5
- Authority
- DK
- Denmark
- Prior art keywords
- pcv2
- vaccine
- group
- pigs
- pcv2 orf2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14041—Use of virus, viral particle or viral elements as a vector
- C12N2750/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (24)
1. En kombinationsvaccine til anvendelse i en fremgangsmåde til (i) nedsættelse af sværhedsgraden af kliniske symptomer forbundet med PCV2-infektion og/eller (ii) forebyggelse af PCV2-infektion, hos smågrise ved indgivelse af en dosis af vaccinen omfatter vaccinen: 1,6 pg til 400 pg/dosis rekombinant PCV2 ORF2-protein, og et PRRS-antigen.
2. Kombinationsvaccine ifølge krav 1 til anvendelse ifølge krav 1, hvor vaccinen omfatter 4 ug til 400 ug/dosis PCV2 ORF2-protein.
3. Kombinationsvaccine ifølge krav 1 til anvendelse ifølge krav 1, hvor vaccinen omfatter 2 pg til 150 pg/dosis PCV2 ORF2-protein.
4. Kombinationsvaccine ifølge krav 1 til anvendelse ifølge krav 1, hvor vaccinen omfatter 3-10 logs PRRS-virus.
5. Kombinationsvaccine ifølge krav 1 til anvendelse ifølge krav 1, hvor PRRS-antigenet er en modificeret levende virus.
6. Kombinationsvaccine ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor indgivelsen af kombinationsvaccinen udføres, når dyrene er 2 til 8 uger gamle.
7. Kombinationsvaccine ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor vaccinen omfatter en ad-juvans.
8. Kombinationsvaccine ifølge krav 7 til anvendelse ifølge krav 7, hvor adjuvansen tilhører klassen af polymerer af acryl- eller methacrylsyre, som er tværbundne.
9. Kombinationsvaccine ifølge krav 7 eller krav 8 til anvendelse ifølge krav 7 eller krav 8, hvor adjuvansen er carbomer.
10. Kombinationsvaccine ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor vaccinen yderligere omfatter rekombinant baculovirus, der koder for PCV2 ORF2-proteinet og cellekultursupernatant.
11. Kombinationsvaccine ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, yderligere til profylakse af infektioner forårsaget af PRRS.
12. Kombinationsvaccine ifølge et hvilket som helst af de foregående krav til anvendelse ifølge et hvilket som helst af de foregående krav, hvor vaccinen er til anvendelse som et lægemiddel, der skal indgives intramuskulært.
13. Anvendelse af rekombinant PCV2 ORF2-protein til fremstilling af en kombinationsvaccine til (i) nedsættelse af sværhedsgraden af kliniske symptomer forbundet med PCV2-infektion og/eller (ii) forebyggelse af PCV2-infektion hos smågrise ved indgivelse af én dosis af nævnte vaccine, idet vaccinen omfatter: 1,6 pg til 400 pg/dosis rekombinant PCV2 ORF2-protein, og et PRRS-antigen.
14. Anvendelse ifølge krav 13, hvor vaccinen omfatter 4 pg til 400 pg/dosis PCV2 ORF2-protein.
15. Anvendelse ifølge krav 13, hvor vaccinen omfatter 2 pg til 150 pg/dosis PCV2 ORF2-protein.
16. Anvendelse ifølge krav 13, hvor vaccinen omfatter 3-10 logs PRRS-virus.
17. Anvendelse ifølge krav 13, hvor PRRS-antigenet er en modificeret levende virus.
18. Anvendelse ifølge et hvilket som helst af kravene 13-17, hvor indgivelsen af kombinationsvaccinen udføres, når dyrene er 2 til 8 uger gamle.
19. Anvendelse ifølge et hvilket som helst af kravene 13-18, hvor vaccinen omfatter en adjuvans.
20. Anvendelse ifølge krav 19, hvor adjuvansen tilhører klassen af polymerer af acryl- eller methacrylsyre, som er tværbundne.
21. Anvendelse ifølge krav 19 eller 20, hvor adjuvansen er carbomer.
22. Anvendelse ifølge et hvilket som helst af kravene 13 til 21, hvor vaccinen yderligere omfatter rekombinant baculovirus, som koder for PCV2 ORF2-proteinet og cellekultur-supernatant.
23. Anvendelse ifølge et hvilket som helst af kravene 13-22, hvor vaccinen er yderligere til profylakse af infektioner forårsaget af PRRS.
24. Anvendelse ifølge et hvilket som helst af kravene 13-23, hvor vaccinen er til anvendelse som et lægemiddel, der skal indgives intramuskulært.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75501505P | 2005-12-29 | 2005-12-29 | |
PCT/US2006/062654 WO2007076520A2 (en) | 2005-12-29 | 2006-12-28 | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1968630T3 DK1968630T3 (da) | 2018-04-23 |
DK1968630T5 true DK1968630T5 (da) | 2018-08-13 |
Family
ID=38218875
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06848471.6T DK1968630T5 (da) | 2005-12-29 | 2006-12-28 | Multivalente pcv2-immunogeniske sammensætninger. |
DK17208901.3T DK3320919T3 (da) | 2005-12-29 | 2006-12-28 | Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille sådanne sammensætninger |
DK10174464.7T DK2275132T3 (da) | 2005-12-29 | 2006-12-28 | Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17208901.3T DK3320919T3 (da) | 2005-12-29 | 2006-12-28 | Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille sådanne sammensætninger |
DK10174464.7T DK2275132T3 (da) | 2005-12-29 | 2006-12-28 | Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem |
Country Status (22)
Country | Link |
---|---|
US (6) | US20080226669A1 (da) |
EP (4) | EP1968630B1 (da) |
JP (2) | JP5394750B2 (da) |
KR (1) | KR101436794B1 (da) |
CN (3) | CN103536914B (da) |
AR (1) | AR058870A1 (da) |
AU (1) | AU2006330491B2 (da) |
BR (2) | BRPI0620859A2 (da) |
CA (1) | CA2635598C (da) |
DK (3) | DK1968630T5 (da) |
ES (3) | ES2666451T3 (da) |
HU (3) | HUE051025T2 (da) |
MX (1) | MX365868B (da) |
MY (2) | MY149398A (da) |
PH (1) | PH12014502525B1 (da) |
PL (3) | PL1968630T3 (da) |
PT (3) | PT1968630T (da) |
RU (2) | RU2488407C2 (da) |
TW (1) | TWI528970B (da) |
UA (1) | UA99708C2 (da) |
WO (1) | WO2007076520A2 (da) |
ZA (1) | ZA200804957B (da) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
US8398994B2 (en) * | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
PL1968630T3 (pl) | 2005-12-29 | 2018-08-31 | Boehringer Ingelheim Vetmedica, Inc. | Multiwalentne immunogenne kompozycje PCV2 |
CN104383526B (zh) | 2005-12-29 | 2018-09-18 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Pcv2免疫原性组合物用于减轻猪临床症状的用途 |
US8470336B2 (en) * | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
US20080241190A1 (en) * | 2006-11-13 | 2008-10-02 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of horses against lawsonia intracellularis |
US20100136060A1 (en) * | 2006-11-22 | 2010-06-03 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
US20100129397A1 (en) * | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
EP2094872B2 (en) | 2006-12-15 | 2020-02-19 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
US8481693B2 (en) | 2007-03-14 | 2013-07-09 | Takeda Vaccines (Montana), Inc. | Virus like particle purification |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
US8398970B2 (en) * | 2007-09-17 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Method of preventing early Lawsonia intracellularis infections |
CN101903041A (zh) * | 2007-12-21 | 2010-12-01 | 辉瑞大药厂 | 经热处理的菌苗,及由这些经热处理的菌苗制备的乳剂疫苗 |
US20110020394A1 (en) * | 2007-12-31 | 2011-01-27 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 virus like particle with foreign amino acid insertion |
EP2242511A4 (en) * | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
WO2009103037A1 (en) * | 2008-02-15 | 2009-08-20 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
TWI449533B (zh) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌(Lawsonia intracellularis)、豬肺炎黴漿菌(Mycoplasma hyopneumoniae)及豬環狀病毒(Porcine circo virus)用疫苗 |
US8444989B1 (en) * | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
KR101079708B1 (ko) * | 2008-07-07 | 2011-11-03 | 주식회사 중앙백신연구소 | 돼지 써코바이러스 관련 질환을 예방하기 위한 pcv-2의전체 바이러스를 포함하는 혼합백신 |
KR100926046B1 (ko) * | 2008-10-16 | 2009-11-11 | 솔로몬유(주) | 엠피쓰리 재생기능을 가진 인형 |
AR078253A1 (es) * | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
SG179037A1 (en) * | 2009-09-10 | 2012-04-27 | Merial Ltd | New vaccine formulations comprising saponin-containing adjuvants |
CN102727883B (zh) * | 2011-05-27 | 2014-05-14 | 华威特(北京)生物科技有限公司 | 猪繁殖与呼吸综合征与猪瘟二联疫苗及其用途 |
HUP1100470A2 (en) * | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
EP2564869A1 (en) | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
CN103083655B (zh) * | 2011-11-02 | 2015-08-26 | 普莱柯生物工程股份有限公司 | 预防和治疗猪圆环病毒2型、副猪嗜血杆菌和猪肺炎支原体感染的疫苗组合物及其制备方法 |
CN102716482B (zh) * | 2012-03-07 | 2014-01-01 | 齐鲁动物保健品有限公司 | 一种高致病性猪繁殖与呼吸综合征活疫苗稀释液 |
UA114503C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
CN103893750B (zh) * | 2012-12-31 | 2015-11-25 | 普莱柯生物工程股份有限公司 | 一种抗猪伪狂犬病、猪流感疫苗组合物及其应用 |
BR102013001893B1 (pt) | 2013-01-25 | 2022-01-25 | Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig | Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso |
EP3587439A3 (en) | 2013-03-01 | 2020-03-11 | Boehringer Ingelheim Animal Health USA Inc. | Improved quantification of vaccine compositions |
CN104043117B (zh) * | 2013-03-11 | 2018-02-13 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
EP2789346A1 (en) | 2013-04-11 | 2014-10-15 | CEVA Santé Animale SA | Fusion polypeptides and vaccines |
US9649370B2 (en) | 2013-05-08 | 2017-05-16 | Protatek International, Inc. | Vaccine for PCV2 and mycoplasma |
JP2015015931A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Umnファーマ | ウイルス様粒子を含む培養物の製造方法 |
CN104288762B (zh) * | 2013-07-19 | 2017-09-12 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
JP6821429B2 (ja) * | 2013-09-25 | 2021-01-27 | ゾエティス・サービシーズ・エルエルシー | Pcv2b分岐ワクチン組成物及び使用方法 |
EA035265B1 (ru) | 2013-10-02 | 2020-05-21 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы |
CN104548083B (zh) * | 2013-10-22 | 2019-05-07 | 洛阳赛威生物科技有限公司 | 一种疫苗组合物及其制备方法和应用 |
CN107837391A (zh) * | 2014-06-24 | 2018-03-27 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
TWI691598B (zh) * | 2015-10-08 | 2020-04-21 | 台灣生物製劑股份有限公司 | 以整體表現細胞作為抗原載體及其於製備疫苗或診斷試劑及篩選單株抗體之應用 |
EP3362467A4 (en) * | 2015-10-16 | 2019-06-12 | Kansas State University Research Foundation | IMMUNOGENIC COMPOSITIONS AGAINST PORCINIC CIRCOVIRUS TYPE 3 AND METHODS OF MAKING AND USING SAME |
EP3432920A1 (en) * | 2016-03-23 | 2019-01-30 | Intervet International B.V. | A vaccine for intradermal application against pcv2 and prrs virus infection |
JP7174698B2 (ja) * | 2016-11-29 | 2022-11-17 | インターベット インターナショナル ベー. フェー. | ブタワクチン |
WO2019121916A1 (en) * | 2017-12-22 | 2019-06-27 | Hipra Scientific, S.L.U. | Intradermal combination vaccine against mycoplasma and porcine circovirus |
CN114746110A (zh) * | 2019-09-26 | 2022-07-12 | Igy免疫技术和生命科学公司 | 靶向非洲猪瘟病毒的疫苗和免疫球蛋白及其制备方法和使用方法 |
BR112023001324A2 (pt) * | 2020-07-24 | 2023-02-14 | Boehringer Ingelheim Animal Health Usa Inc | Combinação de vacina de suíno |
RU2743593C1 (ru) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Пептидные иммуногены и вакцинная композиция против коронавирусной инфекции COVID-19 с использованием пептидных иммуногенов |
RU2743595C1 (ru) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Вакцинная композиция против коронавирусной инфекции COVID-19 |
KR102646305B1 (ko) * | 2021-03-04 | 2024-03-13 | 주식회사 이노백 | 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물 |
CN116813718B (zh) * | 2023-08-30 | 2023-10-27 | 北京瑞阳瑞泰生物科技有限公司 | 一种重组猪圆环病毒2型Cap蛋白三聚体及其表达体系和应用 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3479705A (en) | 1966-12-15 | 1969-11-25 | Miami Brick & Stone Inc Of Mia | Molding apparatus |
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0283085B1 (en) | 1987-03-17 | 1992-11-11 | Akzo N.V. | Adjuvant mixture |
US5069901A (en) | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
DK0454735T3 (da) | 1989-01-23 | 1996-10-07 | Auspharm Int Ltd | Vaccine sammensætning |
US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
US5202430A (en) * | 1990-01-16 | 1993-04-13 | University Of Tennessee | Transmissible gastroenteritis virus genes |
JP3187419B2 (ja) | 1990-05-29 | 2001-07-11 | アメリカン・サイアナミド・カンパニー | ブタ肺炎ワクチンおよびその製造方法 |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
NL9301272A (nl) | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
GB9023111D0 (en) * | 1990-10-24 | 1990-12-05 | Wellcome Found | Expression system |
ES2150419T3 (es) | 1990-11-01 | 2000-12-01 | Univ Iowa State Res Found Inc | Procedimiento de atenuacion bacteriana y vacuna. |
ES2026827A6 (es) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino. |
CA2076744C (en) | 1991-08-26 | 2000-06-27 | Danny W. Chladek | Viral agent associated with mystery swine disease |
US6042830A (en) | 1992-08-05 | 2000-03-28 | Boehringer Ingelheim Vetmedica, Inc. | Viral agent associated with mystery swine disease |
US5580557A (en) * | 1991-10-09 | 1996-12-03 | Iowa State University Research Foundation, Inc. | Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals |
WO1993007898A1 (en) | 1991-10-14 | 1993-04-29 | Akzo Nobel N.V. | Porcine reproductive respiratory syndrome vaccine and diagnostic |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
EP0571648A1 (en) | 1992-05-26 | 1993-12-01 | Chung-Nan Weng | Vaccine protecting against mycoplasmal pneumonia |
ATE197314T1 (de) | 1993-02-08 | 2000-11-15 | Bayer Ag | Verfahren zum vermehren des das reproduktions- und atemwegs-syndrom verursachenden schweinevirus und dessen verwendung als impfstoff. |
ES2074950B1 (es) | 1993-09-17 | 1996-03-16 | Iberica Cyanamid | Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda. |
CA2189979C (en) | 1994-05-10 | 2011-04-19 | Hsien-Jue Chu | Improved modified live brsv vaccine |
US5885823A (en) * | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
ES2102971B1 (es) | 1996-01-25 | 1998-03-01 | Hipra Lab Sa | Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion. |
WO1998006835A2 (en) | 1996-08-16 | 1998-02-19 | The Texas A & M University System | Modifying insect cell gylcosylation pathways with baculovirus expression vectors |
DK0835930T3 (da) * | 1996-10-09 | 2001-06-18 | Akzo Nobel Nv | Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV) |
US7211379B2 (en) * | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
AU2003248395B2 (en) | 1997-10-03 | 2006-03-16 | Merial | Porcine CircoViruses, vaccines and diagnostic reagents |
UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
FR2781159B1 (fr) * | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US6517843B1 (en) * | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
US20060029617A1 (en) | 1997-10-03 | 2006-02-09 | Charreyre Catherine E | Porcine circovirus and Helicobacter combination vaccines and methods of use |
US7192594B2 (en) * | 1997-10-03 | 2007-03-20 | Merial Limited | Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
PT2363488E (pt) * | 1997-12-11 | 2015-01-13 | Univ Belfast | Síndrome multi-sistémica do definhamento pós-desmame de porcos |
WO1999045956A1 (en) * | 1998-03-13 | 1999-09-16 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
US6294176B1 (en) * | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
EP1050584B1 (en) | 1998-11-19 | 2006-10-18 | Azwell Inc. | Recombinant lysophosphatidic acid phosphatase |
FR2789695B1 (fr) * | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
WO2001017556A1 (fr) | 1999-09-07 | 2001-03-15 | Shionogi & Co., Ltd. | Préparations vaccinales administrables par les muqueuses |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
EP1094070A3 (en) | 1999-10-22 | 2002-01-09 | Pfizer Products Inc. | Lawsonia intracellularis proteins, and related methods and materials |
US6656478B1 (en) | 1999-11-12 | 2003-12-02 | Samuel D. Charles | Cross-protective salmonella vaccines |
WO2001045735A2 (en) | 1999-12-21 | 2001-06-28 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
WO2001096377A2 (en) | 2000-06-15 | 2001-12-20 | Purdue Research Foundation | Vaccine for congenital tremors in pigs |
US6808900B2 (en) | 2000-06-15 | 2004-10-26 | Manitoba, University Of | Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) * | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
JP2002247979A (ja) | 2001-02-23 | 2002-09-03 | Nippon Biologicals Inc | マレック病ワクチンおよびその製造方法 |
MY148759A (en) * | 2001-03-27 | 2013-05-31 | Univ Saskatchewan | Methods to culture circovirus |
US20030096377A1 (en) | 2001-06-28 | 2003-05-22 | Virginia Tech Intellectual Properties, Inc. | Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2 |
CZ305781B6 (cs) | 2001-07-02 | 2016-03-16 | Zoetis Services Llc | Výroba vakcíny Mycoplasma hyopneumoniae |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US7279166B2 (en) * | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US6841364B2 (en) * | 2002-01-22 | 2005-01-11 | Protatek International, Inc. | Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof |
WO2003068933A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
US20030199581A1 (en) | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
US20030215455A1 (en) | 2002-05-14 | 2003-11-20 | Bailey Reynolds | Vaccine stabilizer and method of use |
US7335362B2 (en) * | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7223207B1 (en) * | 2002-09-13 | 2007-05-29 | Simon Basyuk | Exercise and massage device |
AU2002951692A0 (en) * | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
EP1599164B1 (en) | 2003-02-03 | 2015-04-08 | Cerebus Biologicals, Inc. | Methods for treating, preventing and detecting helicobacter infection |
US7563449B2 (en) | 2003-04-21 | 2009-07-21 | Pfizer Inc, | Methods for reducing cattle reproductive diseases |
CN1458167A (zh) | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用 |
US7335361B2 (en) | 2003-06-09 | 2008-02-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine |
KR101146545B1 (ko) * | 2003-07-24 | 2012-07-05 | 메리얼 리미티드 | 수중유 에멀젼을 포함하는 백신 제형물 |
SG144909A1 (en) | 2003-07-25 | 2008-08-28 | Boehringer Ingelheim Vetmed | Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
FR2861731B1 (fr) * | 2003-10-30 | 2006-02-24 | Centre Nat Rech Scient | Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations |
CN1942204A (zh) | 2004-04-26 | 2007-04-04 | 株式会社中央疫苗研究所 | 用于猪呼吸病的灭活混合疫苗及其制备方法 |
CN1579553A (zh) | 2004-05-18 | 2005-02-16 | 浙江大学 | Ii型猪圆环病毒核酸疫苗的制备方法及其应用 |
KR100478845B1 (ko) | 2004-06-22 | 2005-03-24 | 채찬희 | 돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물 |
AU2005319716A1 (en) | 2004-06-30 | 2006-06-29 | Id Biomedical Corporation Of Quebec | Vaccine compositions for treating coronavirus infection |
US7833707B2 (en) * | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
RU2007130801A (ru) * | 2005-01-13 | 2009-02-20 | Берингер Ингельхайм Ветмедика Гмбх (De) | Улучшенные вакцины против репродуктивно-респираторного синдрома свиней (prrs) |
US7300785B2 (en) * | 2005-02-03 | 2007-11-27 | Universiteit Ghent | Culturing circular ssDNA viruses for the production of vaccines |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
EP1869471B1 (en) * | 2005-04-13 | 2016-06-08 | Merial, Inc. | Method for porcine circovirus production |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US20080248061A1 (en) | 2005-09-09 | 2008-10-09 | Intervet International B.V. | Pcv-2 Vaccine |
CN104383526B (zh) * | 2005-12-29 | 2018-09-18 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Pcv2免疫原性组合物用于减轻猪临床症状的用途 |
PL1968630T3 (pl) | 2005-12-29 | 2018-08-31 | Boehringer Ingelheim Vetmedica, Inc. | Multiwalentne immunogenne kompozycje PCV2 |
US20100136060A1 (en) | 2006-11-22 | 2010-06-03 | Boehringer Ingelheim Vetmedica, Inc. | Methods of reducing porcine circovirus-associated disease outbreaks |
US20100129397A1 (en) | 2006-12-11 | 2010-05-27 | Boehringer Ingelheim Vetmedica, Inc. | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
EP2094872B2 (en) | 2006-12-15 | 2020-02-19 | Boehringer Ingelheim Animal Health USA Inc. | Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen |
EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
GB0712160D0 (en) | 2007-06-22 | 2007-08-01 | Univ Ghent | Methods and compositions in the treatment of procine circoviral infection |
US20090017064A1 (en) | 2007-07-10 | 2009-01-15 | Wyeth | Methods and Compositions for Immunizing Pigs Against Porcine Circovirus |
US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
EP2242511A4 (en) | 2008-01-23 | 2012-10-24 | Boehringer Ingelheim Vetmed | IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS |
WO2009103037A1 (en) | 2008-02-15 | 2009-08-20 | Boehringer Ingelheim Vetmedica, Inc. | Methods and compositions for reducing the impact of enteric diseases |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
US20100150959A1 (en) | 2008-12-15 | 2010-06-17 | Vectogen Pty Ltd. | PCV 2-Based Methods and Compositions for the Treatment of Pigs |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
US20110150770A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim Vetmedica, Inc. | Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine |
DK2547770T3 (da) | 2010-03-16 | 2020-03-02 | Virginia Tech Intellectual Properties Inc | Levende svækket kimær porcint circovirusvaccine |
WO2012033911A2 (en) | 2010-09-08 | 2012-03-15 | The Johns Hopkins University | Polyionic papilloma virus-like particle (vlp) vaccines |
CN103122352B (zh) | 2012-09-27 | 2015-02-11 | 华中农业大学 | 一种猪圆环病毒2型重组杆状病毒及制备方法和应用 |
EP3587439A3 (en) | 2013-03-01 | 2020-03-11 | Boehringer Ingelheim Animal Health USA Inc. | Improved quantification of vaccine compositions |
WO2014179200A1 (en) | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim Vetmedica, Inc. | Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection |
WO2014187822A1 (en) | 2013-05-22 | 2014-11-27 | Boehringer Ingelheim Espana, S.A. | Method for the reduction of pcv-2 in a herd of swine |
CN105451765A (zh) | 2013-08-23 | 2016-03-30 | 勃林格殷格翰动物保健公司 | 猪圆环病毒2型(pcv2)亚单位疫苗 |
EA035265B1 (ru) | 2013-10-02 | 2020-05-21 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы |
EP3139979B1 (en) | 2014-05-07 | 2023-07-05 | Boehringer Ingelheim International GmbH | Unit, nebulizer and method |
CN107531760A (zh) | 2015-03-30 | 2018-01-02 | 勃林格殷格翰动物保健公司 | Pcv2 orf2载体平台 |
BR112019012504A2 (pt) | 2016-12-23 | 2019-11-19 | Intervet Int Bv | vacina de combinação para suínos |
-
2006
- 2006-12-28 PL PL06848471T patent/PL1968630T3/pl unknown
- 2006-12-28 CA CA2635598A patent/CA2635598C/en active Active
- 2006-12-28 UA UAA200809539A patent/UA99708C2/ru unknown
- 2006-12-28 MX MX2013007854A patent/MX365868B/es unknown
- 2006-12-28 EP EP06848471.6A patent/EP1968630B1/en active Active
- 2006-12-28 RU RU2008130927/15A patent/RU2488407C2/ru active
- 2006-12-28 ES ES06848471.6T patent/ES2666451T3/es active Active
- 2006-12-28 MY MYPI20082355A patent/MY149398A/en unknown
- 2006-12-28 DK DK06848471.6T patent/DK1968630T5/da active
- 2006-12-28 KR KR1020087018734A patent/KR101436794B1/ko active IP Right Grant
- 2006-12-28 AR ARP060105836A patent/AR058870A1/es active Pending
- 2006-12-28 JP JP2008548844A patent/JP5394750B2/ja active Active
- 2006-12-28 TW TW095149377A patent/TWI528970B/zh active
- 2006-12-28 CN CN201310472580.XA patent/CN103536914B/zh active Active
- 2006-12-28 HU HUE17208901A patent/HUE051025T2/hu unknown
- 2006-12-28 AU AU2006330491A patent/AU2006330491B2/en active Active
- 2006-12-28 PL PL10174464T patent/PL2275132T3/pl unknown
- 2006-12-28 CN CN2006800535768A patent/CN101389350B/zh active Active
- 2006-12-28 PL PL17208901T patent/PL3320919T3/pl unknown
- 2006-12-28 US US11/617,414 patent/US20080226669A1/en not_active Abandoned
- 2006-12-28 PT PT68484716T patent/PT1968630T/pt unknown
- 2006-12-28 DK DK17208901.3T patent/DK3320919T3/da active
- 2006-12-28 MY MYPI2012004599A patent/MY180002A/en unknown
- 2006-12-28 DK DK10174464.7T patent/DK2275132T3/da active
- 2006-12-28 ES ES10174464T patent/ES2870583T3/es active Active
- 2006-12-28 EP EP21159529.3A patent/EP3868400A1/en active Pending
- 2006-12-28 PT PT172089013T patent/PT3320919T/pt unknown
- 2006-12-28 WO PCT/US2006/062654 patent/WO2007076520A2/en active Application Filing
- 2006-12-28 PT PT101744647T patent/PT2275132T/pt unknown
- 2006-12-28 BR BRPI0620859-2A patent/BRPI0620859A2/pt not_active Application Discontinuation
- 2006-12-28 CN CN201210141732.3A patent/CN102698263B/zh active Active
- 2006-12-28 RU RU2013114405/15A patent/RU2577129C2/ru active
- 2006-12-28 EP EP10174464.7A patent/EP2275132B1/en active Active
- 2006-12-28 HU HUE06848471A patent/HUE037267T2/hu unknown
- 2006-12-28 HU HUE10174464A patent/HUE054868T2/hu unknown
- 2006-12-28 BR BR122015028489-9A patent/BR122015028489B1/pt active IP Right Grant
- 2006-12-28 ES ES17208901T patent/ES2814473T3/es active Active
- 2006-12-28 EP EP17208901.3A patent/EP3320919B1/en active Active
-
2008
- 2008-06-06 ZA ZA200804957A patent/ZA200804957B/xx unknown
- 2008-06-11 US US12/137,184 patent/US8119143B2/en active Active
-
2012
- 2012-01-09 US US13/346,134 patent/US9101561B2/en active Active
-
2013
- 2013-08-26 JP JP2013174314A patent/JP2013241465A/ja active Pending
-
2014
- 2014-11-12 PH PH12014502525A patent/PH12014502525B1/en unknown
-
2015
- 2015-06-30 US US14/755,972 patent/US9925256B2/en active Active
- 2015-06-30 US US14/755,771 patent/US9925255B2/en active Active
-
2018
- 2018-01-31 US US15/885,113 patent/US10624963B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1968630T5 (da) | Multivalente pcv2-immunogeniske sammensætninger. | |
DK1976558T3 (da) | Pcv2-immunogen sammensætning til at mindske kliniske symptomer i grise. | |
DK2460817T3 (da) | Immunogene PCV2-sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger | |
DK2094872T3 (da) | Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen. | |
DK2481421T3 (da) | Behandling af subklinisk PCVD | |
TW200911284A (en) | Reduction of concomitant infections in pigs by the use of PCV2 antigen | |
HUE033621T2 (en) | PCV2 immunogenic compositions and methods for preparing such compositions | |
MX2008008313A (en) | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |